Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | — | OT |
supposed to be given tdap today but ended up being given with daptacel instead with no reported adverse event; supposed to be given tdap today but ended up being given with daptacel instead with no reported adverse event; Initial information received on 26-Jan-2026 regarding an unsolicited valid non-serious case received from a physician. This case involves a 39 years old male patient who was supposed to be given diphtheria, tetanus and acellular pertussis vaccine but ended up being given with diphtheria-15/tetanus/5 AC pertussis vaccine [Daptacel] instead with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Influenza Vaccine for Immunisation. On 26-Jan-2026, the patient received 0.5 ml of diphtheria-15/tetanus/5 AC pertussis vaccine Suspension for injection (strength- standard, expiry date and lot number not reported) via intramuscular route in the arm NOS (not otherwise specified) for Immunization and was supposed to received diphtheria, tetanus and acellular pertussis vaccine produced by unknown manufacturer (formulation, strength, expiry date and lot number not reported) via unknown route in unknown administration site for prophylactic vaccination (Immunization) with no reported adverse event (product administered to patient of inappropriate age) (wrong product administered) (latency- same day). It was reported that, "Treatment: No treatment, no reaction." Information on the batch number was requested corresponding to the one at time of event occurrence. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
INFLUENZA VACCINE